Bill

A 3074

Requires reporting of positive cytomegalovirus results

2025 Regular Session Introduced by Jeffrey Dinowitz and 4 co-sponsors

Requires labs and clinicians to report positive CMV test results to public health to boost surveillance and protect pregnant people and newborns.

REFERRED TO HEALTH

WeVote Research Nonpartisan

Bill Summary · A 3074

Summary of Assembly Bill A 3074 — Requires Reporting of Positive Cytomegalovirus Results

Overview

Bill Number: A 3074
Title: Requires reporting of positive cytomegalovirus results
Status: REFERRED TO HEALTH (New York Assembly Health Committee)
Introduced: January 23, 2025
Classification: Bill

Purpose and Intent

A 3074 aims to establish mandatory reporting of positive cytomegalovirus (CMV) test results to the state’s public health authority. The underlying goal is to improve surveillance of CMV infections, inform public health action, and support efforts to protect vulnerable populations (notably pregnant individuals and newborns) by enabling more timely data collection and response.

Key Provisions (High-Level)

Reporting Requirement: Laboratories and healthcare providers would be required to report positive CMV test results to the designated public health agency (likely the state health department) within a specified timeframe.
Data Elements: The bill would specify data to be reported, such as test type (e.g., PCR, serology), result status, date of test, patient demographics, and location. (Exact data elements would be enumerated in the bill text.)
Reporting Mechanism: A standardized reporting system or form, potentially with electronic submission, to ensure consistent data collection across providers and laboratories.
Privacy and Use of Data: Provisions would govern data confidentiality and limit access to authorized public health personnel, with the data used to support surveillance, trend analysis, and public health interventions.
Compliance and Enforcement: The measure would establish who must report and may include penalties or enforcement mechanisms for noncompliance (details would be specified in the bill).

Who Is Affected

Primary Affected Entities: Laboratories, clinicians, hospitals, clinics, and other healthcare providers performing CMV testing.
Indirect Effects: Public health agencies responsible for surveillance and response; pregnant individuals and newborns may benefit from improved surveillance-informed actions.

Timeline and Procedural Aspects

Committee Path: Referred to the Health Committee (Health) on January 23, 2025.
Legislative Actions: The record lists the same referral date twice, indicating placement in committee consideration or related procedural steps.
Related Legislation:
- A 1518 and A 8217 (prior-session counterparts)
- S 7662 (companion in the Senate)

Potential Impacts and Considerations

Public Health Impact: Improved data on CMV incidence could enhance monitoring, outbreak detection, and targeted interventions, particularly for congenital CMV and maternal–fetal health.
Operational Considerations: Implementation would require healthcare facilities to adapt workflows for reporting, potentially with an electronic submission system.
Privacy and Equity: Safeguards will be important to protect patient privacy; data use should support public health goals without creating unnecessary exposure.
Costs: Entities may incur costs related to reporting infrastructure and staff time; state implementation costs could be offset by improved health outcomes.

Next Steps

Monitor Health Committee proceedings for amendments, hearings, and potential passage.
Review the bill text and any fiscal notes or analyses for detailed requirements, data elements, timelines, and penalties.
Compare with companion Senate bill S 7662 and prior-session related bills for consistency and potential cross-chamber consensus.

Compiled from official sources — confirm details with the bill’s official record.